Prosidol (Tablets, Solution) Instructions for Use
ATC Code
N02AB (Phenylpiperidine derivatives)
Clinical-Pharmacological Group
Opioid analgesic
Pharmacotherapeutic Group
Analgesics; opioids; phenylpiperidine derivatives
Pharmacological Action
Opioid analgesic agent. It also has sedative, antitussive, and antispasmodic effects. It activates the antinociceptive system and alters the emotional perception of pain. By stimulating opioid receptors in the gastrointestinal tract, it reduces intestinal motility. It does not affect the sphincters. It causes miosis. It has an activating effect on the vomiting center and possesses tocolytic action. It depresses the respiratory center (significantly weaker than morphine).
The duration of analgesic action after oral administration is 4-6 hours, after parenteral administration – 1.5-6 hours (depending on individual sensitivity and dose), 15-30 minutes – after intramuscular administration.
With long-term use (more than 3 months), the analgesic activity decreases (due to the development of tolerance).
Pharmacokinetics
It is well absorbed by any route of administration. Plasma protein binding is 40%.
It is metabolized in the liver to form inactive glucuronidated metabolites.
It is excreted mainly by the kidneys, both as metabolites and in active form.
Indications
Pain syndrome (severe and moderate intensity): malignant neoplasms of various locations; trauma; myocardial infarction; acute pancreatitis; gastric and duodenal ulcer; biliary colic; renal colic; intestinal colic; postoperative period; Leriche’s syndrome; obliterating endarteritis; premedication; general anesthesia (as an analgesic component); painful diagnostic procedures.
ICD codes
| ICD-10 code | Indication |
| I21 | Acute myocardial infarction |
| I73.1 | Obliterative thromboangiitis [Buerger's disease] |
| I74.0 | Embolism and thrombosis of abdominal aorta |
| K25 | Gastric ulcer |
| K26 | Duodenal ulcer |
| K80 | Cholelithiasis [cholelithiasis] (including biliary colic) |
| K85 | Acute pancreatitis |
| N23 | Unspecified renal colic |
| R10.4 | Other and unspecified abdominal pain (colic) |
| R52.0 | Acute pain |
| R52.2 | Other chronic pain |
| T14.9 | Injury, unspecified |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| 4A44.8 | Thromboangiitis obliterans |
| BA41.Z | Acute myocardial infarction, unspecified |
| BD30.10 | Acute thromboembolic occlusion of aorto-iliac segment |
| DA60.Z | Gastric ulcer, unspecified |
| DA63.Z | Duodenal ulcer, unspecified |
| DC11.Z | Cholelithiasis, unspecified |
| DC31.Z | Acute pancreatitis, unspecified |
| DD93.1 | Infantile colic |
| MD81.4 | Other and unspecified abdominal pain |
| MF56 | Renal colic |
| MG30.Z | Chronic pain syndrome, unspecified |
| MG31.Z | Acute pain, unspecified |
| ND56.Z | Unspecified injury of unspecified part of trunk, limb or body region |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets, Solution
For pain syndrome in oncological patients – orally, 25-50 mg 2-3 times/day; daily dose – 50-250 mg (depending on the intensity of pain and previous therapy).
For traumatic pain, gastric ulcer, hepatic, renal and intestinal colic, in the postoperative period – subcutaneously or intramuscularly, 10-40 mg or intravenously – 5-10 mg; daily dose – 20-60 mg.
For premedication – intramuscularly or intravenously by drip, 5-10 mg; for general anesthesia as an analgesic component – intravenously, 0.2-0.7 mg/kg/h.
For acute myocardial infarction – intravenously, 0.1 mg/kg (diluted in 20 ml of 0.9% sodium chloride solution) or intramuscularly 5-10 mg.
For Leriche’s syndrome and obliterating endarteritis – intramuscularly 10-15 mg. Buccally, 10-20 mg, orally – 25 mg. Daily dose – up to 250 mg.
Adverse Reactions
From the central nervous system dizziness, weakness, headache; convulsions, narcolepsy.
From the digestive system dryness of the oral mucosa, nausea, vomiting, impaired liver function, intestinal atony.
From the cardiovascular system decreased blood pressure, bradycardia.
From the genitourinary and urinary system bladder atony, impaired renal function, amenorrhea, decreased libido.
Other allergic reactions, habituation, withdrawal syndrome, with intravenous administration – respiratory depression.
Local reactions pain and hyperemia at the injection site.
Contraindications
Hypersensitivity; depression of the respiratory center; hepatic and/or renal failure; coma; alcohol intoxication; arterial hypotension; organic diseases of the central nervous system; epilepsy and tonic-clonic seizures in history; bronchial asthma; respiratory failure.
With caution pregnancy, lactation period.
Use in Pregnancy and Lactation
With caution pregnancy, lactation period.
Use in Hepatic Impairment
Contraindication — hepatic failure.
Use in Renal Impairment
Contraindication — renal failure.
Special Precautions
It has significant narcotic potential, drug dependence cannot be completely excluded.
Drug Interactions
It enhances the effect of antihypertensive drugs.
Tranquilizers, hypnotics, ethanol, antipsychotic drugs enhance its effect.
Naloxone and naltrexone are specific antagonists.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Sublingual tablets 20 mg: 10 or 20 pcs.
Marketing Authorization Holder
Moscow Endocrine Plant FSUE (Russia)
Dosage Form
| Prosidol | Sublingual tablets 20 mg: 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
Sublingual tablets white, flat-cylindrical, with a bevel.
| 1 tab. | |
| Propionylphenylethoxyethylpiperidine hydrochloride (prosidol) | 20 mg |
Excipients : sucrose – 96.64 mg, sodium saccharin – 1.2 mg, stearic acid – 1.2 mg, gelatin – 0.96 mg.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
Solution for injection 10 mg/1 ml: amp. 5 pcs.
Marketing Authorization Holder
Moscow Endocrine Plant FSUE (Russia)
Dosage Form
| Prosidol solution for injections stabilised 1% | Solution for injection 10 mg/1 ml: amp. 5 pcs. |
Dosage Form, Packaging, and Composition
| Solution for injection | 1 ml |
| Propylphenazone | 10 mg |
1 ml – ampoules (5) – contour cell packs (1) – paper packs.
Noopept, pills 10mg, 50pcs
No-spa pills 40mg, 64pcs
Daivobet, ointment, 30g
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Arbidol, capsules 100mg, 40pcs
Picamilon pills 50mg, 60pcs
Cortexin, 10mg, 5ml, 10pcs
Phenibut-Vertex pills 250mg, 20pcs
Belosalic, lotion solution for external use spray 100ml
Fenotropil pills 100mg, 60pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Belosalic, ointment, 30g
Ingavirin capsules 90mg, 10pcs
OKI, sachets 80mg 2g, 12pcs
Mildronate capsules 500mg, 90pcs
Kagocel pills 12mg, 30pcs
Nootropil pills 800mg, 30pcs
Actovegin pills 200mg, 50pcs 